Tyvaso mechanism of action?

How does Tyvaso work (mechanism of action)?

Tyvaso (treprostinil) is an inhaled formulation of treprostinil, a prostacyclin (PGI2) analog. After inhalation, it helps widen (dilate) pulmonary blood vessels and also inhibits platelet aggregation. In people with pulmonary arterial hypertension, these effects reduce pulmonary vascular resistance, which can improve blood flow through the lungs and lower the pressure load on the heart. [1]

What does it do at the receptor level?

Treprostinil’s main pharmacologic action is prostacyclin receptor (IP receptor) signaling. This leads to smooth muscle relaxation in pulmonary arteries (vasodilation) and helps prevent platelets from clumping (antiplatelet effect). [1]

How is the inhaled route relevant?

Because Tyvaso is inhaled, it targets the pulmonary circulation more directly than systemic administration. That design supports local effects in the lungs, aiming to reduce pulmonary arterial pressure and resistance where the disease is centered. [1]

What clinical outcomes does the mechanism translate into?

By lowering pulmonary vascular resistance through vasodilation, Tyvaso can help improve symptoms and functional capacity in pulmonary arterial hypertension patients. The drug’s mechanism (pulmonary vasodilation plus antiplatelet activity) is the basis for this overall treatment effect. [1]

Sources:
[1] FDA. Tyvaso (treprostinil) prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm